Philadelphia, Pennsylvania--(Newsfile Corp. - January 9, 2023) - The DOJ has announced that Biogen has agreed to pay $900 million to settle federal and state claims that it paid kickbacks to physicians to induce them to prescribe the company's multiple sclerosis drugs from January 1, 2009, through March 18, 2014.
Current long-term Biogen shareholders can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award if appropriate at no cost to them whatsoever.
If you would like to learn more about this matter, visit https://grabarlaw.com/the-latest/biogen-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/150710
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.